CLL Society Medical Advisory Board
CLL Society’s Medical Advisory Board is comprised of leading CLL / SLL experts from across the country. Members generously provide their time and talent to the organization and represent an interprofessional group of well-respected leaders in their field. As a group, they advise CLL Society on a wide range of activities including our educational programming, research efforts, and medical initiatives.
Alexey V. Danilov MD, PhD
Chair
Professor, Department of Hematology
Associate Director, Lymphoma Center
City of Hope National Medical Center
Duarte, CA
Dr. Danilov earned his medical degree and PhD at Yaroslavl State Medical Academy in Russia and completed a fellowship in hematology/oncology at Tufts Medical Center in Boston, Massachusetts. He is a physician-scientist with a background in molecular biology and oncologic drug development and expertise in cancer cell signaling. He leads an independent research program in B-cell malignancies, which bridges the understanding of B-cell biology with early clinical evaluation of novel therapeutics.
As a leader of the Lymphoma Center at the City of Hope National Medical Center, Dr. Danilov guides an effort in experimental therapeutics in lymphoid malignancies. In addition to pre-clinical focus on evaluation of novel targets in the ubiquitin-proteasome system (1) and oncogenic role of cyclin-dependent kinase-9 (2), his group performs correlative science on multiple clinical trials. He received peer-reviewed funding from the National Cancer Institute, Leukemia and Lymphoma Society, American Society of Hematology, Lymphoma Research Foundation and SWOG, and serves as Translational Medicine Chair at SWOG Lymphoma Committee.
Clinically, Dr. Danilov is a practicing medical oncologist specializing in the care of patients with CLL and lymphoma. Building on his pre-clinical discoveries, he launched multiple early-phase clinical trials with novel agents targeting Nedd8-activating enzyme, BTK, PI3K, and SYK. As a member of industry and SWOG committees, he participates in drug development on a global scale.
Matthew S. Davids, MD, MMSc
Co-Chair
Associate Director, Center for Chronic Lymphocytic Leukemia
Dana Farber Cancer Institute
Boston, MA
After obtaining an A.B. cum laude in chemistry at Harvard College, Dr. Davids completed his M.D. cum laude at Yale University School of Medicine. He served as an intern, resident, and assistant chief resident in internal medicine at New York-Presbyterian Weill Cornell Medical Center and Memorial Sloan-Kettering Cancer Center in New York City. He then completed his fellowship in hematology and oncology in Dana-Farber/Partners CancerCare, and a Masters in Medical Science (M.M.S.c.) at Harvard Medical School. He is an attending physician in the Division of Lymphoma, where he serves as the Director of Clinical Research, as well as Associate Director of the DFCI CLL Center. He is also an Associate Professor of Medicine at Harvard Medical School, and attends on the inpatient hematologic malignancies service at Brigham and Women’s Hospital. Dr. Davids has an active translational research program in CLL, focusing on studying apoptosis (in particular Bcl-2 biology) in his laboratory, and leading clinical trials to evaluate novel therapeutic strategies in patients. Much of his work has focused on the clinical development of new therapeutic regimens in CLL utilizing combinations of targeted inhibitors of Bcl-2, B cell receptor pathway kinases, and other novel agents.
Ryan W Jacobs, MD
Dr. Jacobs joined the Levine Cancer Institute in Charlotte, North Carolina in 2015 as an Associate Professor of Internal Medicine where he has served as a chronic lymphocytic leukemia (CLL) and lymphoma specialist is the Director of the Lymphoma Division. Dr. Jacobs graduated from Baylor College of Medicine in Houston, Texas. He then completed his internship and residency in Internal Medicine at Vanderbilt University in Nashville, Tennessee. Dr. Jacobs then returned to Houston to complete his hematology/oncology fellowship at The University of Texas MD Anderson Cancer Center. He functions as a principal investigator on numerous clinical trials. He was promoted to Associate Professor of Internal Medicine through the Wake Forest University School of Medicine in 2024. Dr. Jacobs has both a clinical and research focus in patients with lymphoma and CLL. In his role as a principal investigator, he oversees the clinical trials conducted at Levine Cancer Institute that involve the treatment of patients with lymphoma and CLL. As the CLL expert for the Levine Cancer Institute/Atrium Health network Dr. Jacobs is responsible for creating and overseeing patient care pathways involving the treatment of CLL patients that spans North Carolina, South Carolina, and Georgia. In addition to clinical trials, Dr. Jacobs also has a research interest in real world outcomes of patients with CLL who are on novel therapies, and he has contributed to this field of research. He has published many first author manuscripts and has presented at numerous national and international meetings.
Nitin Jain, MD
Professor of Medicine in the Department of Leukemia at The University of Texas MD Anderson Cancer Center (MDACC) in Houston, Texas
Dr. Jain is a Professor of Medicine in the Department of Leukemia at The University of Texas MD Anderson Cancer Center (MDACC) in Houston, Texas. He earned his medical degree from the All India Institute of Medical Sciences (AIIMS), New Delhi, India in 2002. He completed Internal Medicine residency at the Medical College of Wisconsin, Milwaukee. He then completed a clinical fellowship in Leukemia at MDACC followed by a Leukemia research fellowship at Memorial Sloan-Kettering Cancer Center. He then pursued a fellowship in Hematology/Oncology at The University of Chicago. He joined as a faculty in the Department of Leukemia at MDACC in July 2012. Dr. Jain treats patients with acute and chronic leukemias with focus of patients with chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL). Dr. Jain research interests focus on new drug development for patients with leukemia, especially CLL and ALL. Since 2021, he has also served as Director, Leukemia CAR-T Program within the Department of Leukemia, MDACC. Dr. Jain is Principal Investigator of several investigator-initiated phase I-II clinical trials, including combination targeted therapies (ibrutinib and venetoclax) in CLL, checkpoint inhibitor in Richter transformation, JAK2 inhibitor ruxolitinib in Ph-like ALL, novel CD22 antibody drug conjugate in B-ALL, venetoclax + chemotherapy in B- and T-ALL, ponatinib in T-ALL, and off-the-self allogeneic CARTs in B-ALL. The trial combining ibrutinib and venetoclax was published in the New England Journal of Medicine in 2019. He has published papers in prominent journals including NEJM, Lancet, JAMA Oncology, Journal of Clinical Oncology, Blood, Clinical Cancer Research, Cancer, Leukemia & Lymphoma, and others. He has won many awards during his career including Sardari Lal Kalra Gold Medal in Microbiology from AIIMS and Merit Award from the American Society of Clinical Oncology (ASCO). He secured first rank at the national level in India in the medical school (AIIMS) entrance examination. He received the High-Impact Clinical Research Support Award from MD Anderson Cancer Center in 2014 and 2016. He has served as faculty on American Society of Hematology CRTI workshop from 2017-2019. He is recipient of the Sabin Family Foundation Award in 2018. In 2020, he received MD Anderson Faculty Scholar award. In 2021, he was appointed Director of the CAR-T program for the Leukemia Department, MDACC. In 2022, he received the Leukemia and Lymphoma Society’s Career Development Program Award as well as the Translational Research Program Award.
Adam S Kittai, MD
Associate Professor
Division of Hematology and Medical Oncology
Assistant Director of Lymphoma Clinical Research
CLL Clinical Research Leader
Icahn School of Medicine at Mount Sinai Hospital
New York, NY
Dr. Kittai is an Associate Professor at the Icahn School of Medicine at Mount Sinai in New York, NY where he is the Assistant Director of Lymphoma Clinical Research and CLL Clinical Research Leader. His clinical and research focus is on Chronic Lymphocytic Leukemia (CLL), Richter’s Transformation (RT) and related disorders. He is the primary investigator of multiple investigator-initiated trials exploring the use of small molecule inhibitors with novel designs and deploying cellular therapies for CLL and RT. Dr. Kittai is also interested in re-defining prognostic features for patients with CLL in the era of targeted therapies, as well as defining and mitigating racial disparities that exist in CLL. He is the recipient of the American Society of Clinical Oncology Career Development Award which funds his time for research, and he is an active member on the American Society of Hematology Committee on Training.
Nicole Lamanna, MD
Judy Horrigan Professor of Medicine, Leukemia Service
Director of the Chronic Lymphocytic Leukemia Program
Hematologic Malignancies Section
Herbert Irving Comprehensive Cancer Center
New York-Presbyterian/Columbia University Medical Center
Dr. Nicole Lamanna serves as an Associate Professor of Medicine and Director of the Chronic Lymphocytic Leukemia (CLL) Program on the Leukemia Service for the Hematologic Malignancies Section in the Hematology/Oncology Division at Columbia University Medical Center. Dr. Lamanna specializes in the treatment of adult patients with acute and chronic leukemias. Her area of clinical expertise is in treatment of patients with lymphoid leukemias, specifically chronic lymphocytic leukemia (CLL). Her clinical research focus has been the development of novel combination therapies that include chemo-immunotherapy, immune-modulatory drugs, kinase inhibitors, bcl-2 inhibitors, and monoclonal antibodies. Her research aims have also encompassed the development of safer and more effective therapies for older patients with CLL and the investigation of novel agents for all patients with this disease. She has lectured at international and national meetings and has published in various scientific journals, including Blood, Journal of Clinical Oncology, and the New England Journal of Medicine.
Onyemaechi Okolo-Taku, MD
Medical Oncologist
Ironwood Cancer & Research Centers
Gilbert and Chandler, AZ
Dr. Onyemaechi Okolo-Taku joined Ironwood Cancer & Research Centers in 2021. She has been blessed with a multicultural and multinational upbringing, which has greatly influenced her everyday interactions, her cultural competency, and her work. She was born in Nigeria and lived there with her family until the age of 8, after which she moved to Texas. Subsequently, she spent 3 years in an international boarding school in England. Dr. Okolo- Taku completed her undergraduate degree at The Johns Hopkins University in Baltimore, Maryland. She spent the first two years of medical school at St. George’s University School of Medicine in Grenada and finished off in New York City. While in medical school she did international electives in Nicaragua and the Czech Republic. After NYC, she moved to Tucson, Arizona, where she completed her internal medicine residency, hematology and oncology fellowship, and integrative medicine fellowship.
Dr. Okolo-Taku is a member of ASCO, ASH, SIO, and IOWG. She has always been interested in oncology and hematology due to the fast-moving developments in the field and being able to bring these treatments to her patients. Additionally, she has an interest in evidence-based integrative oncology and completed a fellowship in integrative oncology at the Andrew Weil Center for Integrative Medicine. She has many publications in hematology, oncology, and integrative oncology ranging from case reports to literature reviews, as well as retrospective research. Another big interest of hers is community engagement, understanding and breaking down health disparities, as well as medical education. Her non-work interests include spending time with her husband, her son, and two dogs. She also enjoys traveling, cooking, dining at new restaurants, hiking, gardening, and art.
Javier Pinilla-Ibarz, MD, PhD
Lymphoma Section Head and Director of Immunotherapy
Malignant Hematology Department
H. Lee Moffitt Cancer Center & Research Institute
Tampa, FL
Dr. Pinilla-Ibarz is physician scientist who works as Senior Member, Head of the Lymphoma Section and Director of Immunotherapy in the Department of Malignant Hematology at the H. Lee Moffitt Cancer Center in Tampa, Florida. Dr. Pinilla-Ibarz is also a Professor in the Department of Oncologic Sciences, College of Medicine, University of South Florida, Tampa, Florida.
Dr. Pinilla-Ibarz has been leading the chronic leukemia program at Moffitt since 2006; and its principal interests in the clinic are patients with myeloid and lymphoid chronic leukemia. In this regard, Dr. Pinilla-Ibarz has participated in multiple clinical trials involving several kinase inhibitors many of them now FDA approved. He continues to be involved in the clinical development of new kinases inhibitors through participation in multiple clinical trials.
As Director of Immunotherapy for Malignant Hematology, he has been involved in developing new immunotherapeutic approaches in malignant hematology with special emphasis of restoring the impaired immune response of patients with chronic leukemias. He has participated in several clinical trials of peptide and cellular vaccines in different hematological disorders. He has been involved in the development of a Wilms tumor 1 vaccine for leukemias and other solid tumor now in phase III trial across the world. His laboratory is interested in epigenetic immunoregulation in lymphoid malignancies such as B and T cell lymphomas through the use of epigenetic modifiers such as histone deacetylase inhibitors and hypomethylating agents. Other research focuses are on the interaction of kinase inhibitors with the immune system and how to use these drugs to improve current immune therapeutics approaches. Dr. Pinilla-Ibarz frequently presents his findings at annual meetings of the American Hematology Association and the American Society of Clinical Oncology and he lectures in other national/international meetings. His work has been published in journals including New England Journal of Medicine, Blood, Nature Immunology, Journal of Leukocyte Biology and Leukemia. He has also authored multiple book chapters.
Dr. Pinilla-Ibarz received both his MD and PhD from the University of Zaragoza, School of Medicine, Spain. He completed his residency in medicine and a fellowship in Hematology at La Paz University Hospital in Madrid, Spain; and after he moved to the US, he also completed a residency in Internal Medicine at Cornell Medical Center and a fellowship in Hematology/Oncology at the Memorial Sloan Kettering Cancer Center in New York City.
Jennifer A. Woyach, MD
Professor and Director of the Division of Hematology in the Department of Internal Medicine at The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute
Dr. Woyach is a Professor and Director of the Division of Hematology in the Department of Internal Medicine at The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute. She holds the D Warren Brown Chair of Leukemia Research and serves as co-Director of the Leukemia Research Program within the OSU Comprehensive Cancer Center.
Dr. Woyach earned her medical degree from The Ohio State University College of Medicine and Public Health, where she also completed a residency in internal medicine, serving as Chief Resident in her final year. Afterwards, she remained at The Ohio State University to complete a fellowship in hematology and medical oncology and joined the faculty in 2012.
Dr. Woyach’s research interests include chronic lymphocytic leukemia (CLL) and other hematologic malignancies. Her laboratory research focuses on the role of Bruton’s Tyrosine Kinase (BTK) in the development and expansion of CLL, as well as therapeutic BTK inhibition in CLL using murine and cellular models. Her research also examines resistance to BTK inhibitor therapy. Her clinical research focuses on novel agents in CLL. She is the PI for multiple early stage clinical trials investigating novel targeted therapies for CLL and other hematologic malignancies, and also mentor junior faculty members in the development and conduct of Phase I studies.
Among her achievements, Dr. Woyach is a recipient of the 2015 American Society for Clinical Investigation Young Physician-Scientist Award. Her work has been featured in several medical publications, including NEJM, Journal of Clinical Oncology, Lancet Oncology, Blood and Cancer Discovery. She is a member of the leukemia committee of the Alliance for clinical trials in oncology, the women in hematology subcommittee of ASH, and is a standing member of the iwCLL.
Laura J. Zitella, MS, RN, ACNP-BC, AOCN
Hematology, Blood & Marrow Transplant, and Cellular Therapies Program
UCSF Helen Diller Family Comprehensive Cancer Center
Associate Clinical Professor, School of Nursing
University of California San Francisco
San Francisco, CA
Laura is a Nurse Practitioner who cares for patients with blood or bone marrow cancers, such as lymphoma, multiple myeloma, and leukemia. With more than 25 years of experience caring for people with CLL, she has expertise in chemotherapy, immunotherapy, targeted therapy, medications utilized in clinical trials, blood and marrow transplants, symptom management, and palliative care.
Laura earned her Master’s degree in Nursing at the University of Illinois Chicago College of Nursing, where she also completed training to become a certified Acute Care Nurse Practitioner. She specialized in oncology and immunology.
Laura has delivered hundreds of educational presentations to national and international audiences. She has authored numerous peer-reviewed publications, medical textbook chapters, and has created many web-based medical education modules. She also co-edited the textbook Hematologic Malignancies in Adults.
Laura has received a number of awards, including the Award for Excellence from the Oncology Nursing Society, the DAISY Award for Extraordinary Nurses, and Stanford Health Care’s inaugural Advanced Practice Provider of the Year Award.
